BiotechTube

Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community Acquired Bacterial Pneumonia

Conditions

Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection

Trial Timeline

Jan 1, 2011 → May 1, 2014

NCT ID
NCT01602874

About Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin

Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin is a phase 3 stage product being developed by Pfizer for Community Acquired Bacterial Pneumonia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01602874. Target conditions include Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection.

What happened to similar drugs?

2 of 12 similar drugs in Community Acquired Bacterial Pneumonia were approved

Approved (2) Terminated (1) Active (9)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00914888Phase 3Withdrawn
NCT01602874Phase 3Withdrawn

Competing Products

17 competing products in Community Acquired Bacterial Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
27
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
tigecyclinePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3
32
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
tigecyclinePfizerPhase 3
40
Zinforo (ceftaroline fosamil)PfizerPre-clinical
26
Tigecycline + LevofloxacinPfizerPhase 3
40
AzithromycinPfizerPhase 3
40
TelithromycinSanofiApproved
43
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 daysEnanta PharmaceuticalsPhase 2
21